AstraZeneca's Evusheld Receives CHMP's Recommendation for Approval in the EU for the Pre-Exposure Prophylaxis of COVID-19 in the EU
Shots:
- AstraZeneca's Evusheld is recommended for marketing authorisation in the EU for the pre-exposure prophylaxis of COVID-19 in adults & adolescents aged ≥12yrs.
- The CHMP recommendation was based on the P-III (PROVENT) trial of Evusheld (150mg of tixagevimab & 150mg of cilgavimab, IM) which showed a 77% reduction in risk of developing symptomatic COVID-19 over PBO at the primary analysis & 83% reduction @6mos. median analysis with protection lasting @6mos. & was well-tolerated
- The new data showed that the therapy retained potent neutralizing activity against the emerging & highly transmissible BA.2 subvariant, reduced viral burden & limited inflammation in lungs across all Omicron variants
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
